US Breast Conserving Surgery Market 2025 – 2034

Reports Description

As per the US Breast Conserving Surgery Market analysis conducted by the CMI team, the US Breast Conserving surgery market is expected to record a CAGR of 7.67% from 2025 to 2034. In 2025, the market size was USD 831.93 Million. By 2034, the valuation is anticipated to reach USD 1613.56 Million.

Overview

The growth of the US Breast Conserving surgery market is credited to increased prevalence of breast cancer coupled with support provided by patient awareness campaigns and mammography screening programs. Such initiatives have resulted in a rise in early detection rates, thereby making a greater number of patients eligible for various Breast Conserving procedures such as quadrantectomy and lumpectomy. Plus, there is a good preference for the procedures preserving breast function and appearance, particularly among the younger patients, which does align with the norms pertaining to Breast Conserving surgery (BCS).

Expansion of ambulatory surgical settings is amongst the key drivers of the US Breast Conserving surgery market as it does offer a patient-friendly, cost-effective alternative to the inpatient hospital procedures. Such settings are increasingly abreast with experienced staff, advanced surgical technologies, and streamlined processes that render them suitable for procedures such as BCS, which have shorter recovery times and are less invasive.

Key Trends & Drivers

• Rise in Healthcare Spending

Rise in funding has let hospitals invest in advanced technology, conduct awareness programs about various surgical options, and train more specialists, thereby encouraging the patients to prefer breast conserving procedures over mastectomies.

The American Medical Association has published an article stating that health spending in the US rose by 7.5% in the year 2023 (to US$ 4.9 Tn). Moreover, expansions pertaining to insurance coverage under the higher healthcare budgets are reducing the costs further, thereby making surgery monetarily practical for a greater number of women.

Numerous public health campaigns funded by increased healthcare spending are apprising the patients regarding the advantages of Breast Conserving surgery, thereby driving the demand further. Besides, enhanced post-operative rehabilitation and care services that are supported by the higher budgets are improving recovery outcomes, which ends up making the procedure more appealing.

What’s trending in the US Breast Conserving Surgery Market?

Wireless seed markers along with radiofrequency devices are rapidly replacing conventional wire-guided methods related to locating non-palpable lesions, thereby offering less discomfort and more surgical flexibility to the patients. Also, AI and real-time fluorescence imaging systems are aiding surgeons in identifying and excising cancerous tissue with a higher level of accuracy, thereby notably reducing the need for repetition of surgeries and enhancing cosmetic results.

Radiofrequency ablation (RFA) is a minimally invasive method gaining popularity, particularly for those who are not candidates for conventional surgery. Plus, there is oncoplastic surgery, which does combine removal of the tumor with plastic surgery techniques for improving aesthetic outcome, thereby resulting in better satisfaction of patients.

What would be Business Impact of the US tariffs on the US Breast Conserving Surgery Market?

The US tariffs on various imported surgical supplies as well as devices are likely to increase the costs of Breast Conserving surgery (BCS). IN other words, raised prices of essential syringes, gloves, surgical instruments, and the like are reducing the profit margins for clinics and making the procedures costlier for patients. The other repercussions could be the market players absorbing costs or moving production to the US for maintaining competitiveness, thereby increasing the probability of disruption of the supply chain for BCS on the whole.

Key Threats

• The Cost Factor

Advancements that include intraoperative imaging, wireless tumor localization, oncoplastic surgery, and margin assessment tools need pricey instruments with discrete skills, which do divert revenue and raise costs related to the primary procedure. Also, utilization and upkeep of such high-tech devices do increase institutional costs. These factors may compel the small entrants to give a second thought regarding the US Breast Conserving surgery market.

Opportunities

Breast Conserving surgeries are witnessing a revolution, as the technological advancements are enhancing the accuracy of breast surgeries and the safety involved in treating cancers while retaining the intactness of the breast. For example, wireless tumor localization systems (SCOUT and Magseed), real-time margin assessment, and intraoperative imaging let surgeons accurately locate and eliminate tumors while sparing the healthy tissue. Such tools aid in mitigating the chance of repeated surgeries.

A publication in Nature (2020) did find that analysis of more than 91,000 mammograms from the US and the UK combined demonstrated that using AI resulted in notably lower false-positive rates, i.e., almost 6% lower in the US, which does support the role in improvement of early diagnosis.

Category Wise Insights

By Procedure

• Lumpectomy

Lumpectomy segments hold more than 40% of the market share. This could be owing to lumpectomy being the very first line of surgical treatment for the patients who are seeking effective cancer control with minimum cosmetic disruption. It is broadly accepted as one of the oncologically safe alternatives to mastectomy for stage I as well as II cancers, and that too with equivalent long-term survival outcomes when accompanied with radiation therapy. Moreover, technological advancements like wireless localization, intraoperative margin assessment tools, and real-time imaging have rendered lumpectomy more efficient. As such, lower psychological impact, shorter recovery time, and compatibility with ASCs are contributing to wide clinical adoption.

• Quadrantectomy

Quadrantectomy facilitates treatment of more complex or larger tumors, thereby widening application of Breast Conserving surgery. This procedure utilizes oncoplastic techniques for improving cosmetic outcomes. For tumors with ductal or segmental spread, quadrantectomy does offer surgical curability in comparison with conservative techniques by ascertaining the affected tissue’s more comprehensive removal. AI-powered tools that help in analyzing tissue at the time of surgery are capable of ensuring 100% removal of the tumor while minimizing loss of healthy tissue.

• Segmental Mastectomy

Segmental mastectomy offers a patient-centric approach to early-stage breast cancer, thereby providing less psychological impact, better cosmetic outcomes, and quicker recovery in comparison with mastectomy. Advancements in radiation therapy and oncoplastic surgery, along with conducive insurance coverage, further promote Breast Conserving surgeries and contribute to the growth of the market. Coverage from the major insurers such as Medicare does enable access to Breast Conserving surgery.

By Product

• Tumor Localization Devices

The tumor localization devices segment is likely to witness the highest CAGR during the forecast period. This could be credited to the rising shift toward minimally invasive, precision-guided procedures. With non-palpable, early-stage breast tumors getting detected frequently through the advanced screening methods, demand for precise intraoperative localization has increased. Conventional wire-guided localization, while in use, is being replaced by several wireless alternatives like radiofrequency tags, radar-based systems, and magnetic seed markers that offer enhanced patient comfort, better scheduling flexibility, and raised surgical precision.

• Surgical Excision Devices

Surgical excision devices segment held a sizable market share in 2024. The growth could be owing to the important role played by these devices in quadrantectomy and lumpectomy. They include electrosurgical units, scalpels, radiofrequency ablation tools, and ultrasonic dissectors, which are fundamental with regard to the removal of tumors and used in almost all Breast Conserving surgeries. Their clinical familiarity, reliability, and compatibility with several surgical techniques do render them indispensable in ambulatory and hospital settings.

• Margin Assessment Devices

The major advantage of margin assessment devices is their ability to assess tumor margins in real-time at the time of surgery, thereby letting surgeons determine how many cancerous cells prevail. The timely feedback does prevent the common issue of positive margins, which, in turn, does necessitate a second surgery for removal of remaining cancer. Achievement of negative margins in the first attempt helps surgeons in completing the procedure in a more efficient manner, thereby resulting in cutting down on operating time on the whole.

• Intraoperative Imaging & Navigation Devices

Intraoperative ultrasound and fluorescence-guided systems do make provisions for real-time visualization, thereby letting surgeons identify as well as remove all the cancer cells, thereby reducing the positive margins. Preservation of healthy breast tissue by enabling removal of only the essential quantity of tissue (reduced excision volumes) results in better cosmetic results with a higher patient satisfaction quotient. Real-time guidance helps surgeons in centralizing the tumor within the specimen, thereby enhancing the precision and quality of the resection.

By End-use

• Hospitals

The hospital segment leads the US Breast Conserving surgery market with respect to end-use. This could be due to their ability to offer comprehensive surgical care, access to multidisciplinary cancer treatment teams, and advanced technologies. Hospitals, particularly huge academic medical centers with specialized oncology facilities, are abreast with the infrastructure needed for performing complex BCS procedures like lumpectomy with oncoplastic reconstruction, intraoperative imaging, and wireless localization.

• Ambulatory Surgery Centers

Ambulatory surgical centers segment is anticipated to witness the quickest CAGR during the forecast period due to increased demand for outpatient-based, cost-effective surgical care. ASCs do offer numerous advantages, inclusive of shorter procedure times, lower risks of infection, reduced hospital stays, and higher operational efficiency, thereby rendering them ideal for early-stage breast cancer surgeries. Plus, conducive reimbursement networks, expansion of ASCs all over the US, and patients’ preference for discharge on the same day are expediting the shift.

• Oncology/Specialty Clinics

Oncology/specialty clinics do incorporate technological advancements, expertise, and multidisciplinary care inclusive of oncoplastic surgery. They do enable higher rates on the part of BCS by facilitating integration of radiologists, surgical oncologists, and pathologists, thereby enhancing safety, quality, and aesthetic outcomes of BCS. Such specialized centers do drive patient preference all through their patient-centric environment, shorter wait times, and economical outpatient services.

How is AI impacting the US Breast Conserving Surgery Market?

AI models are being designed for predicting the risk of breast cancer and determining the need for surgery in this regard. Plus, using histopathological slides and breast imaging scans, these models are used for classifying, detecting, grading, segmenting, and staging breast tumors. The preoperative applications are inclusive of patient education and displaying accurate tumor resection with margin status assessment. Also, AI is used for predicting postoperative complications, cancer recurrence, and survival.

Report Scope

Key Developments

The US Breast Conserving market is witnessing a significant organic and inorganic expansion. Some of the key developments include –

• In May 2025, Perimeter Medical Imaging AI, Inc.’s results of its pivotal trial evaluating next-generation B-Series OCT with ImgAssist AI 2.0 (better called Perimeter B-Series) were presented during a scientific session of the 26^th Annual Meeting of the American Society of Breast Surgeons (ASBrS).

• In April 2025, Innoblative Designs, Inc. did receive approval from the US FDA for Investigational Device Exemption (IDE). This approval does allow the company to move forward with its US feasibility study, which would assess the effectiveness and safety of the SIRA RFA Electrosurgical Device in the patients who are undergoing Breast Conserving surgery (BCS).

• In January 2025, Lumicell, Inc., announced the launch of LumiSystem (a technology devised for enhancing breast cancer surgery), which integrates LUMISIGHT (an optical imaging agent fluorescing in areas of suspected cancerous tissue) and Lumicell Direct Visualization System (DVS) (one of the advanced imaging devices offering real-time fluorescence-guided scanning of the breast cavity at the time of lumpectomy procedures). The company confirmed that both the components have been approved by the US FDA.

Leading Players

The US Breast Conserving surgery market is highly competitive, with a large number of service providers globally. Some of the key players in the market include:

• Hologic Inc.
• Argon Medical Devices
• Merit Medical Systems
• KUBTEC
• Stryker
• Mammotome (Danaher)
• CairnSurgical Inc.
• Lumicell Inc.
• Innoblative Designs
• Perimeter Medical Imaging AI
• Others

These firms apply a plethora of strategies to enter the market, including innovations, mergers and acquisitions, and collaboration. The US Breast Conserving surgery market is shaped by the presence of diversified players that compete based on product innovation, vertical integration, and cost efficiency.

The US Breast Conserving Surgery Market is segmented as follows:

By Procedure

• Lumpectomy
• Quadrantectomy
• Segmental Mastectomy

By Product

• Tumor Localization Devices
• Surgical Excision Devices
• Margin Assessment Devices
• Intraoperative Imaging & Navigation Devices

By End-use

• Hospitals
• Ambulatory Surgery Centers
• Oncology/Specialty Clinics